Literature DB >> 7471319

Amphotericin B plus combination chemotherapy for extensive non-small cell bronchogenic carcinoma.

G Sarna, B B Lowitz, P A Ganz, M J Cline.   

Abstract

Sixteen patients with extensive non-small carcinoma of the lung were treated with methotrexate, vincristine, cyclophosphamide, and adriamycin. Cyclophosphamide and adriamycin were administered after pretreatment with amphotericin B. Amphotericin B-related toxicity was mild; cytotoxic chemotherapy-related toxicity was tolerable. The partial response rate was 12.5% and median survival was between 19 and 20 weeks. Response rate and survival were not superior to those of a similar drug combination lacking amphotericin B.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7471319     DOI： 10.1007/bf00435410

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  9 in total

1.  Amphotericin B-induced sensitivity to actinomycin D in drug-resistant Hela cells.

Authors:  J Medoff; G Medoff; M N Goldstein; D Schlessinger; G S Kobayaski
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

2.  Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia.

Authors:  G Medoff; F Valeriote; R G Lynch; D Schlessinger; G S Kobayashi
Journal:  Cancer Res       Date:  1974-05       Impact factor: 12.701

3.  Chemo-immunotherapy for unresectable bronchogenic carcinoma.

Authors:  G P Sarna; B B Lowitz; C M Haskell; F J Dorey; M J Cline
Journal:  Cancer Treat Rep       Date:  1978-05

4.  Potentiation of anticancer agent cytotoxicity against sensitive and resistant AKR leukemia by amphotericin B1.

Authors:  F Valeriote; G Medoff; J Dieckman
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

5.  Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine.

Authors:  P A Chahinian; D J Arnold; J M Cohen; D P Purpora; I S Jaffrey; A S Teirstein; P A Kirschner; J F Holland
Journal:  JAMA       Date:  1977-05-30       Impact factor: 56.272

6.  Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.

Authors:  C A Presant; C Klahr; J Olander; D Gatewood
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

7.  Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.

Authors:  J D Bitran; R K Desser; T R DeMeester; M Colman; R Evans; A Billings; M Griem; L Rubenstein; C Shapiro; H M Golomb
Journal:  Cancer Treat Rep       Date:  1976-09

8.  Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma.

Authors:  A N Krutchik; A U Buzdar; G R Blumenschein; J G Sinkovics
Journal:  Cancer Treat Rep       Date:  1978-10

9.  Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.

Authors:  C A Presant; C Klahr; R Santala
Journal:  Ann Intern Med       Date:  1977-01       Impact factor: 25.391
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.